The complete, interactive record on oxygen carriers and perfusion technique in kidney transplantation — a century of blood-substitute history, the cell biology of ischemia-reperfusion injury, every major published trial, the strongest long-term graft-survival data that exists, and exactly where BHOC's own record stands inside all of it. No claim on this page goes further than its citation.
I didn't come to BHOC as an investor or a scientist. I came to it the way I come to everything in this work — as someone who has spent nearly two decades on the losing end of the clock every donor organ is racing against. Cold ischemia time isn't an abstraction to me; it's the number that, more than almost anything else in the transplant process, quietly decides how long a graft is going to last. For years, the industry's answer to it has been a cooler and a stopwatch.
Perfusion technique is not a footnote in transplant medicine. It is one of the only levers we have ever proven, in a 672-patient randomized trial with ten years of follow-up, to change how long a kidney actually survives.
That is the fact that convinced me this deserves the Foundation's full voice, not a passing mention. We are not talking about a theoretical mechanism here — we are talking about a documented 27% reduction in ten-year graft failure risk, simply from changing how an organ is handled between donor and recipient. Oxygen carriers like the class BHOC belongs to are the next iteration of that same lever: not a replacement for good perfusion technique, but a way to make it dramatically more powerful, by giving the perfused organ something closer to what a beating heart would have given it.
What makes BHOC's lineage matter to me isn't a marketing claim — it's that the class of molecule it descends from has real, published, peer-reviewed evidence of doing something ice alone cannot: actively fighting ischemia-reperfusion injury during the exact window that predicts delayed graft function, and delayed graft function is one of the strongest known predictors of how long a transplanted kidney survives.
I'm not going to overstate where BHOC specifically stands. You'll see the honest gap in its own evidence laid out plainly below, because a foundation that hides its own gaps has no business asking federal agencies to close theirs. But I find the underlying science compelling enough, and the stakes for patients like me high enough, that closing that gap is worth this Foundation's voice, its research hours, and its outreach to the people who decide what reaches a transplant center. Graft longevity is not a soft outcome. It's the whole point.
— Jeff Parke, Founder, Cold Ischemia Foundation
Every kidney that leaves a donor enters a race against a clock that has no snooze button. From the moment blood flow stops, the organ is running on stored oxygen and nothing else. Static cold storage — a cooler, a preservation solution, ice — slows that clock. It does not stop it, and it does nothing to give the tissue what it actually needs during the wait: oxygen. That is the gap oxygen carriers are built to close, and it is the gap this page exists to document.
The interval an organ spends without blood flow, cooled but not perfused with oxygen, between recovery and transplant. Longer CIT is independently associated with worse graft outcomes across decades of registry data.
How the organ is handled during that interval — static cold storage vs. machine perfusion, with or without oxygen. The single most-proven intervention for improving long-term graft survival is a change in technique, not a drug.
Hemoglobin-based compounds — from bovine, marine, or synthetic sources — engineered to carry and release oxygen outside the body, without red blood cells. Their organ-preservation use is a newer, narrower application of decades-old blood-substitute science.
The strongest published evidence in this entire field does not come from an oxygen carrier at all — it comes from a 672-patient randomized trial of machine perfusion technique, with results that held up for ten years. Oxygen carriers are the next layer on top of that proven foundation, not a replacement for it. This page treats that distinction as load-bearing.
What follows is organized to let you check every claim against its source: a dedicated tab on graft longevity and why perfusion technique moves that number more than almost anything else in transplant medicine; the clinical problem oxygen carriers target; the full history of the field going back to 1898; the cell biology of how these molecules actually work; a side-by-side comparison of the carriers that have real published data; the clinical evidence itself, trial by trial; the safety controversy that has kept this class out of routine IV use for twenty years; an honest accounting of where BHOC specifically stands inside all of it; a glossary; and a full reference list.
A transplant that fails in year eight is not a success story with an asterisk — it is a second illness, a second waitlist, and for many patients a second organ that may never come. Graft longevity, not just whether a transplant "works" on day one, is the outcome the Foundation cares about, and it is also the outcome for which perfusion technique has the strongest documented long-term effect of anything short of donor-recipient matching itself.
That trial is the single most important data point on this entire page, and it did not involve an oxygen carrier at all — it compared hypothermic machine perfusion (continuous, gentle pumping of cold preservation solution through the organ's vasculature) against simply packing the kidney in ice. The fact that technique alone produced a durable, decade-long survival advantage is the strongest evidence in transplant medicine that how an organ is perfused is not a logistical detail — it is a clinical intervention in its own right.
Delayed graft function (DGF) — when a transplanted kidney doesn't work immediately and the recipient needs dialysis in the first week — is the mechanistic link between perfusion quality and long-term survival. DGF is not just an inconvenient early setback: registry studies consistently associate it with higher rates of acute rejection, shorter graft half-life, and reduced long-term function, even in kidneys that eventually "catch up" on creatinine clearance. It is the earliest visible signal of ischemia-reperfusion injury, and it is the outcome most oxygen-carrier organ studies report because it is measurable within days, not years.
Why oxygen carriers enter this picture: machine perfusion moves cold solution through the organ, but standard perfusion solutions carry almost no oxygen. Adding an oxygen carrier to the perfusate is the logical next step on the same lever that already produced the 27% figure above — not a separate idea, but an intensification of the one intervention already proven to change ten-year outcomes.
Most people assume the danger to a donor kidney is the time it spends without blood flow. That's only half of it. The more damaging event happens the moment blood flow is restored.
Blood flow stops. Cells switch to anaerobic metabolism, ATP depletes, and metabolic waste (lactate, hydrogen ions) accumulates. Cold storage slows this but does not stop it.
Sodium-potassium pumps fail without ATP. Cells swell. Mitochondria begin to destabilize. The longer this phase runs, the more primed the tissue is for the next phase.
Oxygen returns abruptly. Damaged mitochondria overproduce reactive oxygen species (ROS) in a burst that damages cell membranes, proteins, and DNA — this is the paradox: oxygen, the thing the tissue needed, is also what triggers the worst of the injury.
Damaged cells release signals (including IL-6) that recruit immune cells, amplify inflammation, and can trigger delayed graft function and, over time, chronic allograft injury.
This is why the field has converged on a counterintuitive idea: the safest way to protect an organ from reperfusion injury is not to withhold oxygen for as long as possible, but to reintroduce it gradually and in a controlled way before transplant — letting the tissue's own antioxidant defenses come back online under low, steady oxygen tension rather than being hit with a sudden flood at the moment of vascular reconnection in the recipient. That is the clinical logic behind hypothermic oxygenated perfusion (HOPE) and behind adding an oxygen carrier to a machine-perfusion circuit: controlled, gradual reintroduction rather than an abrupt one.
An inflammatory cytokine used across the preclinical literature as a proxy for reperfusion injury severity. Lower post-perfusion IL-6 in oxygen-carrier-treated organs (vs. standard solution) is one of the most consistently reported findings in preclinical kidney and liver perfusion studies.
A byproduct of anaerobic metabolism. Elevated perfusate lactate signals ongoing cellular stress from inadequate oxygen delivery; oxygen-carrier-supplemented perfusion has been associated with faster lactate clearance in porcine kidney models.
Understanding where BHOC sits requires understanding the whole arc: real early promise, a genuine and well-documented safety crisis in systemic IV use, and a slower, more careful second act focused on organ preservation rather than blood replacement. Filter the timeline below by category.
Early experiments infuse hemoglobin stripped of red-cell membrane (stroma) into animals, establishing that free hemoglobin outside a red cell can be prepared and administered — and that raw stroma-free hemoglobin causes kidney toxicity, a lesson the field would spend a century engineering around.
Researchers learn to chemically cross-link and polymerize hemoglobin molecules, preventing them from breaking into toxic subunits in the kidney and extending circulating half-life — the core engineering approach nearly every modern HBOC still uses.
Continuous cold pumping of preservation solution through a donor organ's vasculature is developed as an alternative to simple cold storage, laying the technical foundation that today's oxygen-carrier perfusion research builds directly on top of.
HIV-era fears about the blood supply and battlefield trauma-care needs drive major pharmaceutical investment into hemoglobin-based blood substitutes intended for wide systemic IV use — trauma, surgery, battlefield resuscitation — not organ preservation. Baxter, Biopure, Northfield Laboratories and others enter the field.
A Baxter-sponsored trauma trial is stopped after HemAssist recipients showed a 46% 28-day mortality rate vs. 17% in the control arm (P=.003) — a signal serious enough to end the program and become one of the field's most cited cautionary data points.
Biopure's bovine-derived hemoglobin carrier receives approval in South Africa for treating anemia in adult surgical patients — the first and, to date, one of very few regulatory approvals anywhere for a hemoglobin-based oxygen carrier for use in humans. It was never approved by the FDA for human use in the United States.
Northfield Laboratories' PolyHeme trauma resuscitation trial reports a 13% 30-day mortality rate vs. 10% in controls — not statistically significant on its own, but consistent with a troubling pattern across the class that regulators and researchers were now tracking closely.
Organ Recovery Systems commercializes a portable hypothermic machine perfusion device for kidneys, moving HMP from research labs into routine clinical logistics. It would go on to be used in over 400 transplant programs across 40+ countries.
Sangart's MP4, a PEG-conjugated hemoglobin carrier engineered specifically for high oxygen affinity and low vasoactivity (to avoid the hypertension problems seen in earlier carriers), reports a 57% vs. 50% adverse outcome rate in one surgical trial (P=.18, not significant) — better-tolerated than earlier-generation products but still not enough for approval.
A meta-analysis in JAMA pools 16 randomized controlled trials across five hemoglobin-based oxygen carrier products and finds a statistically significant increased risk of death (RR 1.30) and myocardial infarction (RR 2.71) associated with HBOC use. This single analysis becomes the reason no hemoglobin-based oxygen carrier holds full FDA approval for systemic IV use in the United States today, nearly two decades later.
The landmark 672-patient, paired-kidney randomized trial of hypothermic machine perfusion vs. static cold storage publishes in NEJM, establishing the strongest technique-level evidence in the field's history — and reframing "perfusion" itself, apart from any drug or carrier, as a proven clinical lever.
Following the 2008 safety crisis, serious HBOC research money and attention shift away from whole-body trauma/surgical resuscitation and toward a narrower, arguably safer application: adding oxygen carriers directly to ex-vivo machine perfusion circuits, where the carrier never enters the recipient's own bloodstream at all.
Groups led by Swiss and Dutch transplant centers develop HOPE — brief, controlled oxygenation of an organ during otherwise-cold storage or the final phase of machine perfusion — and begin reporting reduced biliary complications in liver transplantation and improved early function in kidneys from higher-risk donors.
On September 30, 2022, M101 — a marine-derived (lugworm) extracellular hemoglobin from French biotech HEMARINA — becomes the first oxygen carrier in the world CE-marked specifically as an additive to organ preservation solution, a narrower and more specific approval pathway than any earlier HBOC ever achieved. It is approved for organ preservation use in Europe, not as a systemic IV blood substitute.
A published clinical study of M101 added to static cold storage in kidney transplantation (n=58) reports delayed graft function in 6.9% of the M101 group vs. 26.1% of controls (P=.038), and median time to normal creatinine of 7 days vs. 13 days (P=.020) — the largest published kidney-specific oxygen-carrier dataset to date.
Published November 5, 2025 in NEJM, the ten-year follow-up to the original 2009 trial confirms the machine-perfusion survival advantage held for a full decade — extended-criteria donor kidneys at 69.6% vs. 60.1% survival, DCD kidneys at 81.4% vs. 75.6%, a 27% lower overall risk of graft failure.
A red blood cell is more than a hemoglobin delivery vehicle: its membrane, its size, and its flow behavior all matter, especially in the narrow, cold, sluggish vasculature of a stored organ. Free hemoglobin behaves differently, for better and worse.
Free hemoglobin molecules are roughly 1/500th the volume of a red blood cell and carry no membrane, letting them perfuse through microvasculature and edematous tissue that swollen, sluggish capillaries may partially restrict — a real concern in a cold, post-ischemic organ.
Unshielded free hemoglobin binds nitric oxide (a vasodilator) far more aggressively than hemoglobin inside a red cell, which can cause vasoconstriction and hypertension — the mechanism widely believed to underlie the cardiovascular signal seen in the 2008 Natanson meta-analysis. Later-generation carriers are specifically engineered (via molecular size, PEGylation, or natural NO-binding differences) to reduce this effect.
Different carriers can be engineered or naturally exhibit different oxygen-binding affinities (P50), which determines how readily they release oxygen to hypoxic tissue — a property organ-preservation formulations can tune differently than a systemic resuscitation product would want.
Unlike most HBOCs, HEMARINA's M101 is a naturally occurring extracellular hemoglobin (no red-cell membrane to begin with, and no cross-linking chemistry required) from the marine worm Arenicola marina, which is reported to carry oxygen without the same NO-scavenging profile seen in mammalian-hemoglobin-derived carriers — part of why its organ-preservation approval pathway looks different from earlier systemic HBOCs.
Lower P50 means the carrier holds onto oxygen more tightly (releases it less readily); higher P50 means it releases oxygen more easily to surrounding tissue. Organ-preservation applications generally favor formulations engineered to release oxygen efficiently even at the low oxygen tensions typical of a cold, stored organ.
This is the most important interactive tool on this page. It exists to stop any single carrier — including BHOC — from borrowing the credibility of the whole class. Click a chip to compare.
This is the evidence base for the HBOC class as a whole, organized by how directly it applies to kidney transplantation.
| Study | Carrier | n | Key finding | P-value |
|---|---|---|---|---|
| M101 + static cold storage, kidney transplant | M101 | 58 | DGF: 6.9% vs. 26.1% (control) | .038 |
| Same cohort, secondary endpoint | M101 | 58 | Time to normal creatinine: 7 vs. 13 days | .020 |
| Study | n | Key finding | Follow-up |
|---|---|---|---|
| Moers et al., NEJM (paired-kidney RCT) | 672 | 27% lower risk of graft failure, machine perfusion vs. cold storage | 10 years |
| Same trial, original endpoints | 672 | Reduced delayed graft function, machine perfusion arm | 1 year |
| Model | Carrier class | Key finding |
|---|---|---|
| Porcine kidney, ex-vivo perfusion | HBOC-supplemented perfusate | Lower post-reperfusion IL-6 and faster lactate clearance vs. standard perfusate |
| Porcine/rodent liver models | HOPE (oxygenation, no exogenous carrier) | Reduced biliary complication rates in donor livers, especially DCD grafts |
| Trial | Product | Outcome | P-value |
|---|---|---|---|
| Baxter trauma trial | HemAssist (DCLHb) | 46% vs. 17% 28-day mortality — trial halted | .003 |
| Northfield trauma trial | PolyHeme | 13% vs. 10% 30-day mortality | NS |
| Sangart surgical trial | MP4 (Hemospan) | 57% vs. 50% adverse outcomes | .18, NS |
| Natanson meta-analysis (16 RCTs, 5 products) | Class-wide | RR 1.30 death, RR 2.71 MI | significant |
Tier 4 is why HBOCs remain outside routine IV clinical practice in the United States. Tiers 1–3 represent the field's deliberate pivot away from that failure mode: toward localized, ex-vivo organ perfusion where the carrier never circulates in the recipient's own bloodstream, and toward the technique-level gains (Tier 2) that don't require a novel molecule at all.
Any page that talks about the promise of oxygen carriers without addressing this directly is not being straight with you. Here is the actual history.
In 2008, Charles Natanson and colleagues published a meta-analysis in JAMA pooling 16 randomized controlled trials of five different hemoglobin-based oxygen carrier products, covering more than 3,700 patients across trauma, surgical, and stroke indications. The pooled analysis found a statistically significant increase in the risk of death (relative risk 1.30) and myocardial infarction (relative risk 2.71) among patients who received an HBOC compared to controls.
That finding effectively ended the era of hemoglobin-based oxygen carriers as systemic IV resuscitation products in the United States. No HBOC holds full FDA approval for human IV use today, and companies including Biopure and Northfield Laboratories either exited the field or were acquired. Hemopure (HBOC-201) remains approved in South Africa for surgical anemia — the exception that proves how narrow the path to approval has been.
Free hemoglobin outside a red blood cell membrane binds and scavenges nitric oxide, a key vasodilator, far more readily than hemoglobin protected inside a red cell. Unchecked NO scavenging causes vasoconstriction, which can raise blood pressure and is believed to contribute to the cardiovascular events seen in the pooled trials. Later-generation carriers (larger molecular size, PEGylation, different natural binding kinetics) were specifically engineered to reduce this effect, with mixed but improving results (see MP4/Hemospan above).
Not directly. Every trial in the Natanson meta-analysis involved systemic IV administration into a patient's own circulation for trauma, surgical blood loss, or stroke. Ex-vivo machine perfusion — where the carrier stays in a closed circuit outside the body and is flushed from the organ before implantation — is a mechanistically and clinically different exposure. This is precisely why the field pivoted toward organ preservation after 2008, and why M101's 2022 approval was specifically for that narrower use, not systemic IV administration.
Yes — HEMARINA's M101 (HEMO2life) received CE mark approval on September 30, 2022, specifically as an additive to organ preservation solution in Europe. This is the first and, as of this writing, the clearest regulatory precedent for oxygen-carrier use in organ preservation, distinct from the systemic IV pathway that failed in the 2000s.
Neither. BHOC has not published human trial data of its own in any application, so it has neither generated a safety signal nor been cleared of one. It inherits the open scientific questions of its molecular class until it generates its own data. See the BHOC Today tab for the full, direct statement on this.
BHOC belongs to the broader hemoglobin-based oxygen carrier class described throughout this page. The underlying chemistry — hemoglobin engineered for extracorporeal oxygen delivery — is real, decades-studied science with genuine peer-reviewed evidence behind the class.
BHOC's own public developer materials describe applications in trauma and surgical blood-loss settings. As of this writing, we are not aware of any published, peer-reviewed kidney-transplant-specific clinical trial data for BHOC.
This is the honest gap. No organ-preservation-specific trial, of any size, has been published for BHOC as of this writing. Every kidney-specific number on this page (M101's DGF and creatinine data, the Moers survival data) comes from other products or from technique alone — not from BHOC.
A published, peer-reviewed kidney-perfusion study — even a small preclinical one, the way M101's evidence base started — is the single most important next step for BHOC's credibility in this specific application. This Foundation's research advocacy is aimed, in part, at helping that data get generated and published.
We are not going to dress this gap up. Every kidney-specific outcome number cited elsewhere on this page — the DGF reduction, the creatinine timeline, the ten-year survival advantage — belongs to a different product, or to perfusion technique itself, not to BHOC. What BHOC has is a real molecular lineage in a real and increasingly evidenced field, and a founder who believes closing its own evidence gap is worth doing publicly rather than quietly. That is the honest state of the record as of this writing.
Why publish this section at all, rather than simply not mentioning the gap? Because the entire argument this Foundation makes to regulators, clinicians, and donor families rests on trustworthiness. A page that quietly blurred BHOC's status with the published HBOC-201 and M101 literature would be indistinguishable, to a skeptical reader, from every other unproven product that borrows a field's credibility without doing its own work. We would rather you trust every other claim on this page because you can see we didn't do that here.
Some primary-source journal pages (PubMed, PMC, Wiley, LWW) block automated access behind CAPTCHA or subscription walls. Where a primary source could not be directly verified, we relied on the abstract, a secondary reporting source, or a press release describing the same published finding, and note that below. We welcome corrections — contact the Foundation if any citation here should be revised.
If perfusion technique alone can cut ten-year graft failure risk by more than a quarter, then every serious improvement to how organs are perfused — including oxygen delivery — deserves rigorous, honest attention. That's what this page, and this Foundation, are for.